Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.
Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-related lymphoproliferative disorders. Quantitative determination of serum EBV DNA permits early diagnosis of an AIDS-related non-Hodgkin's lymphoma, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.
Fleisch
Felix
F
Department of Internal Medicine, Cantonal Hospital, Chur, Switzerland. felix.fleisch@scag.gr.ch
Reinhart
Walter H
WH
Brand
Brigit
B
Berger
Christoph
C
D019380:Anti-HIV Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004279:DNA, Viral / Q000097:blood*; D004317:Doxorubicin / Q000008:administration & dosage; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D013557:Switzerland; D014750:Vincristine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D004279:DNA, Viral; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone